IMV Inc. (TSE:IMV – Get Free Report) shares fell 1.8% during trading on Monday . The company traded as low as C$1.07 and last traded at C$1.12. 15,761 shares were traded during mid-day trading, a decline of 72% from the average session volume of 56,822 shares. The stock had previously closed at C$1.14.
IMV Trading Down 1.8 %
The company has a current ratio of 2.93, a quick ratio of 2.32 and a debt-to-equity ratio of 1,231.01. The firm has a market capitalization of C$13.12 million, a price-to-earnings ratio of -0.18 and a beta of 1.52. The business has a 50 day simple moving average of C$1.12.
About IMV
IMV Inc operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer.
Featured Articles
- Five stocks we like better than IMV
- Short Selling: How to Short a Stock
- The 3 Hottest Insiders Buys This Month
- Stock Average Calculator
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- What Are the FAANG Stocks and Are They Good Investments?
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.
